Enveric Biosciences publishes two peer-reviewed research papers

Enveric Biosciences (ENVB) announced the publication of two peer-reviewed research papers describing innovative bioproduction strategies for creating therapeutic compounds. While Enveric’s EB-003 is manufactured using established synthetic chemistry methods common to the pharmaceutical industry, these publications highlight the company’s broader scientific leadership in pioneering bioproduction approaches that expand the tools available for drug discovery. The papers were published in ACS Chemical Biology and BioDesign Research. The first paper, published in ACS Chemical Biology describes how researchers engineered microbial systems to produce a wide range of indolethylamine derivatives relevant to neuroplastogen drug discovery. In total, the effort generated 279 compounds, including 17 novel N-acetylated molecules that were purified and tested for activity across receptors linked to psychiatric disease. Nearly all showed interaction with the melatonin receptor, and several also engaged serotonin receptor subtypes. The results show that microbial bioproduction can efficiently generate large, diverse libraries of molecules suitable for high-throughput screening in neuropsychiatric research. The second paper reported the first bioproduction method for MDMA and related compounds. The team developed an integrated approach using engineered yeast and enzymatic processing to create phenylacetylcarbinol derivatives, which were then advanced through a streamlined pathway that ultimately yielded MDMA and the analog 6-chloro-MDMA. This approach provides a novel alternative to traditional chemical synthesis, which depends on controlled precursor materials, and establishes a foundation for further optimization of microbial methods to produce psychoactive derivatives under investigation for conditions such as post-traumatic stress disorder. First-in-human studies are anticipated in 2026.